Delivered Q4 and FY2025 revenue above guidanceBest ARR performance of the year in Q4 with total ending ARR of $124 millionRecord percentage of ARR in multi-year agreements and record number of ...
(Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results